Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab.

Claudia CampaniJessica Bamba-FunckBertille CampionSabrina SidaliLorraine BlaiseNathalie Ganne-CarriéAlix DemoryOlivier SutterEdouard LarreyManon EvainHaroun GhannouchiMathilde WagnerFabio MarraAngela SuttonManon Allaire Jean Charles Nault

Published in: Liver international : official journal of the International Association for the Study of the Liver (2022)

AFP early response at 3 weeks predicts oncological outcomes in HCC patients treated with AtezoBev and combination with ALBI grade refines prognostic discrimination.

Keyphrases

robot assisted
minimally invasive
prostate cancer
type diabetes
skeletal muscle
rectal cancer
newly diagnosed